ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 700

Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease

Ofir Elalouf1, Elizabeth Fireman2, David Levartovsky1, Ilana Kaufman1, Ori Rogovski3, Ori Elkayam1, Dan Caspi1 and Daphna Paran1, 1Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 2Pulmonary and Allergic diseases, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 3Internal Medicine ward, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

In a previous study, performed 9±3.6 years ago 74 asymptomatic patients with systemic lupus erythematosus (SLE) and or antiphospholipid syndrome (APS) who fulfilled the ACR criteria for diagnosis,  underwent lung function testing.  A significantly low diffusion capacity (DLCO) ranging from 45% to 70% was recorded in 28 of the 74 (37.8%) patients who were all free of respiratory symptoms.  This study aims to assess the clinical importance and predictive value of a low diffusion capacity in asymptomatic patients with SLE or APS.

Methods

Asymptomatic patients with SLE and /or APS who were found to have a low DLCO in the previous study were contacted. Of the 28 patients, 15 were recruited and reevaluated in the current study [SLE with APS (n=7), SLE without APS (n=7); primary APS (n=1)].  A detailed  history,  physical examination, nail bed capillaroscopy,  current laboratory tests and lung function tests including DLCO were obtained.

 Results

During a surveillance period of 9±3.6 years none of the patients developed lung disease. Diffusion capacity corrected for alveolar volume (DLCO/VA) improved in the study group during this period from 61.3% ± 6.3 to 77% ± 12.7% (p=0.006). Lung function tests including total lung capacity (TLC) and forced expiratory volume in 1s (FEV1) remained within normal limits. Capillaroscopy studies did not reveal changes compatible with scleroderma in any of the patients.

 Conclusion

Low diffusion capacity findings on lung function testing does not have a positive predictive value for the development of future lung disease in patients with SLE who are free of respiratory symptoms. Our results suggest that a finding of low diffusion capacity in asymptomatic patients with SLE does not necessarily require further evaluation and imaging and may improve spontaneously over time. Further studies in a larger group of patients are needed to validate these findings.


Disclosure:

O. Elalouf,
None;

E. Fireman,
None;

D. Levartovsky,
None;

I. Kaufman,
None;

O. Rogovski,
None;

O. Elkayam,
None;

D. Caspi,
None;

D. Paran,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-lung-diffusion-capacity-in-asymptomatic-patients-with-systemic-lupus-erythematosus-does-not-predict-future-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology